Why India's Novartis ruling is not patent Armageddon

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Why India's Novartis ruling is not patent Armageddon

The Supreme Court’s denial of Novartis’s Glivec patent has prompted dire warnings about patent protection in India, but practitioners say that the decision was just a straightforward application of the law

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
more from across site and ros bottom lb

More from across our site

Sources at four firms explain how changes to USPTO fees provide opportunities to give clients strategic counselling
Gift this article